With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Six-monthly HIV drug, lenacapavir, reduced HIV incidence by 96 per cent in trial. Affordability and supply remain key hurdles for rollout.

PRNewswire/ -- "According to the latest BCC Research study, "The global ADCs market is showing a rapid growth trend, with growth rates of 36.5% and 40.7% ...

Host Katya Adler and our BBC teams guide you through one major global news story each episode. From Beijing to Boston, Baghdad to Bangalore, our unrivalled reach will take you beyond the headlines ...

The RSC and 37 other organisations have signed a letter to Chancellor Rachel Reeves that reiterates the long-term social and economic benefits of R&D activity in the UK. David Baker, Demis Hassabis ...